Harmony Biosciences' cannabidiol drug fails Phase 3 trial in fragile X

Harmony Biosciences said its experimental drug ZYN002, a synthetic cannabidiol gel, failed a Phase 3 study in people with fragile X syndrome, which affects a small subset of people with autism ...